GlassScriptPhysician profile
John Marino
NPI 1568442473
$17,491.82
in general payments reported to CMS, 2019-2025
46 companies · $2,638 in 2025
The $2,638 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,215 · 2020: $1,733 · 2021: $2,227 · 2022: $2,196 · 2023: $2,946 · 2024: $3,537 · 2025: $2,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,838 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,838.03 |
| Education | $282.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,929.13 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $2,181.98 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,312.87 | 2020-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,136.57 | 2019-2025 | Xifaxan |
| Amgen INC. | $906.99 | 2019-2025 | Repatha, Tezspire, Otezla |
| Genentech USA, INC. | $629.29 | 2019-2024 | Xolair |
| Novo Nordisk INC | $616.34 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $615.95 | 2019-2025 | Ofev, Jardiance |
| Abbvie INC. | $595.70 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $543.35 | 2022-2025 | Qelbree, Qelbree |
| Genzyme Corporation | $533.05 | 2021-2025 | |
| Lilly USA, LLC | $511.99 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $428.84 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Actelion Pharmaceuticals US, INC. | $301.07 | 2024-2025 | Opsumit, Uptravi |
| Teva Pharmaceuticals USA, INC. | $260.62 | 2019-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $241.13 | 2019-2021 | |
| Amarin Pharma, INC. | $218.91 | 2019-2021 | |
| Exact Sciences Corporation | $209.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mallinckrodt Enterprises LLC | $191.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $186.38 | 2019-2022 | |
| Philips North America LLC | $186.36 | 2019-2025 | Vest Therapy Und |
| Paratek Pharmaceuticals, INC. | $169.49 | 2021-2024 | Nuzyra |
| Pfizer INC. | $168.99 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.33 | 2021-2022 | |
| Inogen, INC. | $155.11 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Alkermes, INC. | $135.71 | 2022-2025 | Aristada, Lybalvi |
| Novartis Pharmaceuticals Corporation | $130.51 | 2019-2023 | |
| Insmed, INC. | $90.20 | 2025 | Arikayce |
| Esperion Therapeutics, INC. | $89.75 | 2024 | Nexletol |
| Mallinckrodt Hospital Products INC. | $85.83 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $73.42 | 2025 | Gvoke Hypopen |
| Allergan, INC. | $66.20 | 2019-2020 | |
| Verona Pharma, INC. | $63.02 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $61.95 | 2024 | Voquezna |
| Astellas Pharma US INC | $39.51 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $38.58 | 2024 | Kristalose |
| Shield Therapeutics INC | $36.88 | 2023-2024 | Accrufer |
| Shire North American Group INC | $33.64 | 2019 | |
| Ironwood Pharmaceuticals, INC | $29.17 | 2022 | |
| Electromed, INC. | $23.59 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.45 | 2023 | Rexulti |
| Eisai INC. | $18.59 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.70 | 2020 | |
| Horizon Therapeutics Plc | $15.09 | 2020 | |
| Vistapharm, INC. | $14.99 | 2021 | |
| Currax Pharmaceuticals LLC | $14.19 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Marino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.